MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- ORCHID PHARMA LTD - MYLAN (US)
ORCHID PHARMA LTD vs MYLAN (US) - Comparison Results
ORCHID PHARMA LTD 
Change
Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 ORCHID PHARMA LTD  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ORCHID PHARMA LTD Sep-13 |
MYLAN Dec-14 |
ORCHID PHARMA LTD/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 194 | 4,292 | - | |
| Low | Rs | 35 | 3,025 | - | |
| Sales per share (Unadj.) | Rs | 276.5 | 1,469.4 | - | |
| Earnings per share (Unadj.) | Rs | -79.2 | 177.0 | - | |
| Cash flow per share (Unadj.) | Rs | -43.5 | 284.9 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 53.9 | 730.5 | - | |
| Shares outstanding (eoy) | m | 70.45 | 378.37 | - | |
| Bonus/Rights/Conversions | ESOP | OI | - | ||
| Price / Sales ratio | x | 0.4 | 2.5 | 16.6% | |
| Avg P/E ratio | x | -1.4 | 20.7 | -7.0% | |
| P/CF ratio (eoy) | x | -2.6 | 12.8 | -20.5% | |
| Price / Book Value ratio | x | 2.1 | 5.0 | 42.4% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 8,067 | 1,384,310 | 0.6% | |
| No. of employees | `000 | 2.8 | 25.0 | 11.2% | |
| Total wages/salary | Rs m | 2,527 | 0 | - | |
| Avg. sales/employee | Rs Th | 6,956.1 | 22,239.8 | 31.3% | |
| Avg. wages/employee | Rs Th | 902.5 | 0 | - | |
| Avg. net profit/employee | Rs Th | -1,993.0 | 2,679.1 | -74.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 19,477 | 555,994 | 3.5% | |
| Other income | Rs m | 407 | -3,241 | -12.6% | |
| Total revenues | Rs m | 19,884 | 552,754 | 3.6% | |
| Gross profit | Rs m | 1,103 | 138,278 | 0.8% | |
| Depreciation | Rs m | 2,519 | 40,835 | 6.2% | |
| Interest | Rs m | 5,227 | 23,983 | 21.8% | |
| Profit before tax | Rs m | -6,236 | 70,220 | -8.9% | |
| Minority Interest | Rs m | 20 | -288 | -6.8% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 511 | 0 | - | |
| Tax | Rs m | -125 | 2,953 | -4.2% | |
| Profit after tax | Rs m | -5,580 | 66,979 | -8.3% | |
| Gross profit margin | % | 5.7 | 24.9 | 22.8% | |
| Effective tax rate | % | 2.0 | 4.2 | 47.7% | |
| Net profit margin | % | -28.7 | 12.0 | -237.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,014 | 488,793 | 2.3% | |
| Current liabilities | Rs m | 32,060 | 382,138 | 8.4% | |
| Net working cap to sales | % | -108.1 | 19.2 | -563.3% | |
| Current ratio | x | 0.3 | 1.3 | 26.9% | |
| Inventory Days | Days | 95 | 78 | 121.5% | |
| Debtors Days | Days | 34 | 107 | 31.3% | |
| Net fixed assets | Rs m | 29,440 | 128,628 | 22.9% | |
| Share capital | Rs m | 705 | 19,661 | 3.6% | |
| Net worth | Rs m | 3,800 | 276,384 | 1.4% | |
| Long term debt | Rs m | 9,018 | 412,891 | 2.2% | |
| Total assets | Rs m | 46,510 | 1,113,249 | 4.2% | |
| Interest coverage | x | -0.2 | 3.9 | -4.9% | |
| Debt to equity ratio | x | 2.4 | 1.5 | 158.9% | |
| Sales to assets ratio | x | 0.4 | 0.5 | 83.8% | |
| Return on assets | % | -0.8 | 8.2 | -9.3% | |
| Return on equity | % | -146.9 | 24.2 | -606.0% | |
| Return on capital | % | -3.7 | 13.6 | -27.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,682 | 73,086 | 2.3% | |
| From Investments | Rs m | -9,860 | -57,638 | 17.1% | |
| From Financial Activity | Rs m | 6,644 | -19,258 | -34.5% | |
| Net Cashflow | Rs m | -1,535 | -3,810 | 40.3% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.02 Rs / USD
Compare ORCHID PHARMA LTD With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ORCHID PHARMA LTD With: PFIZER J.B.CHEMICALS ELDER PHARMA PIRAMAL ENTERPRISES STERLING BIOTECH
|
| |
Today's Market
Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)
Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.
Related Views On News
ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)
Aug 24, 2018 | Updated on Aug 24, 2018For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
More Views on NewsMost Popular
It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)
Dec 6, 2018My latest StockSelect recommendation ticks all the boxes of a great safe stock.
Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)
Dec 11, 2018RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.
Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)
Dec 7, 2018This stock has corrected 30% from peak and looks attractive at these valuations.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)
Dec 5, 2018PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.
More|
| |
ORCHID PHARMA LTD SHARE PRICE
Dec 17, 2018 (Close)
TRACK ORCHID PHARMA LTD
- Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ORCHID PHARMA LTD
ORCHID PHARMA LTD 8-QTR ANALYSIS
COMPARE ORCHID PHARMA LTD WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.